Investigation of miR-21, miR-150, miR-155 Expression Levels in Chronic Myeloid Leukemia Patients
Purpose: In this study, the relationship between CML and the expression levels of miR-21, miR-150, and miR-155, which could be used in the follow-up of CML patients, was investigated. Materials and Methods: RNA and miRNA were extracted from peripheral blood samples of patient and control samples....
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Kirsehir Ahi Evran University
2025-04-01
|
| Series: | Ahi Evran Medical Journal |
| Subjects: | |
| Online Access: | https://dergipark.org.tr/tr/download/article-file/3263928 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Purpose: In this study, the relationship between CML and the expression levels of miR-21, miR-150, and miR-155, which could be used in the follow-up of CML patients, was investigated.
Materials and Methods: RNA and miRNA were extracted from peripheral blood samples of patient and control samples. Targe-ted miRNA expression levels from cDNA samples were analyzed by real-time PCR method.
Results: miRNA expression level was determined as 1.0 in the control group. In the newly diagnosed group, the mean miR-21 fold change was 0.6, miR-150 fold change was 0.3, and miR-155 fold change was 0.5. fold changes for miR-21, miR-150 and miR-155 were found to be 1.4, 0.5 and 2.4 fold, respectively, in the imatinib treatment group. In the nilotinib treatment group, miR-21 level was 3.5, miR-150 level 0.5, and miR-155 level 4.3. In the dasatinib treatment group, fold change was 0.8 for miR-21, 2.1 for miR-150, and 0.5 for miR-155. The mean miR-21 level was found to be 3.2, miR-150 level 1.0 and miR-155 level 2.8. MiR-150 levels were found to be lower in the newly diagnosed group, imatinib group and nilotinib group than in the control samples. This difference between the new diagnosis group (p=0.07484) and the nilotinib group (p=0.01541) is statistically signi-ficant. No significant difference was found between patients and controls in terms of miR-21 and miR-155 levels.
Conclusion: These results support that miRNA-150 can be used as a parameter in the monitoring of treatment of CML patients and can contribute to the early detection of drug resistance. |
|---|---|
| ISSN: | 2619-9203 |